<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0701256534
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2007
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        FUNZOL 150MG CAPSULES
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FLUCONAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        150
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        15.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1055]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Dallah Health Care Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J02AC01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>FUNZOL is one of a group of medicines called &ldquo;antifungals&rdquo;. The active substance is Fluconazole.<br />FUNZOL is used to treat infections caused by fungi and may also be used to stop you from getting a candidal infection. The most common cause of fungal infections is a yeast called Candida.&nbsp;<br />Adults<br />You might be given this medicine by your doctor to treat the following types of fungal infections:&nbsp;<br />□ Cryptococcal meningitis &ndash; a fungal infection in the brain<br />□ Coccidioidomycosis &ndash; a disease of the bronchopulmonary system<br />□ Infections caused by Candida and found in the blood stream, body organs (e.g. heart, lungs) or urinary tract<br />□ Mucosal thrush - infection affecting the lining of the mouth, throat and denture sore mouth<br />□ Genital thrush &ndash; infection of the vagina or penis<br />□ Skin infections - e.g. athlete&#39;s foot, ringworm, jock itch, nail infection<br />You might also be given FUNZOL to:<br />□ Stop cryptococcal meningitis from coming back<br />□ Stop mucosal thrush from coming back&nbsp;<br />□ Reduce recurrence of vaginal thrush<br />□ Stop you from getting an infection caused by Candida (if your immune system is weak and not working properly)<br />Children and adolescents (0 to 17 years old)&nbsp;<br />You might be given this medicine by your doctor to treat the following types of fungal infections:<br />□ Mucosal thrush - infection affecting the lining of the mouth, throat<br />□ Infections caused by Candida and found in the blood stream, body organs (e.g. heart, lungs) or urinary tract<br />□ Cryptococcal meningitis &ndash; a fungal infection in the brain<br />You might also be given FUNZOL to:&nbsp;<br />□ Stop you from getting an infection caused by Candida (if your immune system is weak and not working properly).<br />□ Stop cryptococcal meningitis from coming back<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>□ If you are allergic to Fluconazole, to other medicines you have taken to treat fungal &nbsp;infections or to any of the other ingredients of this medicine (listed in section 6). The symptoms may include itching, reddening of the skin or difficulty in breathing&nbsp;<br />□ If you are taking astemizole, terfenadine (antihistamine medicines for allergies)<br />□ If you are taking cisapride (used for stomach upsets)&nbsp;<br />□ If you are taking pimozide (used for treating mental illness)<br />□ If you are taking quinidine (used for treating heart arrhythmia)<br />□ If you are taking erythromycin (an antibiotic for treating infections).<br />Take special care with FUNZOL:<br />Talk to your doctor or pharmacist before taking FUNZOL:<br />□ If you have liver or kidney problems<br />□ If you suffer from heart disease, including heart rhythm problems<br />□ If you have abnormal levels of potassium, calcium or magnesium in your blood<br />□ If you develop severe skin reactions (itching, reddening of the skin or difficulty in breathing).<br />□ If you develop signs of &lsquo;adrenal insyfficincy&rsquo; where the adrenal glands do not produce adequate amounts of certain steroid hormones such as cortisol (chronic, or long lasting fatigue, muscle weakness, loss of appetite, weight loss, abdominal pain).<br />□ If you have ever developed a severe skin rash or skin peeling, blistering and/or mouth sores after taking fluconazole<br />Serious skin reactions including drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported in association with fluconazole treatment.&nbsp;<br />Stop taking FUNZOL and seek medical attention immediately if you notice any of the symptoms related to these serious skin reactions described in section 4.<br />Talk to your doctor or pharmacist if the fungal infection does not improve, as alternative antifungal therapy may be needed.<br />Taking other medicines with FUNZOL:<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.<br />Tell your doctor immediately if you are taking astemizole, terfenadine (an antihistamine for treating allergies) or cisapride (used for stomach upsets) or pimozide (used for treating mental illness) or quinidine (used for treating heart arrhythmia) or erythromycin (an antibiotic for treating infections) as these should not be taken with FUNZOL (see section: &ldquo;Do not take FUNZOL&rdquo;).<br />There are some medicines that may interact with FUNZOL. Make sure your doctor knows if you are taking any of the following medicines as a dose adjustment or monitoring may be required to check that the medicines are still having the desired effect:<br />□ Rifampicin or rifabutin (antibiotics for infections)<br />□ Abrocitinib (used to treat atopic dermatitis, also known as atopic eczema)<br />□ Alfentanil, fentanyl (used as anaesthetic)<br />□ Amitriptyline, nortriptyline (used as anti-depressant)<br />□ Amphotericin B, voriconazole (anti-fungal)<br />□ Medicines that thin the blood to prevent blood clots (warfarin or similar medicines)&nbsp;<br />□ Benzodiazepines (midazolam, triazolam or similar medicines) used to help you sleep or for anxiety&nbsp;<br />□ Carbamazepine, phenytoin (used for treating fits)<br />□ Nifedipine, isradipine, amlodipine, verapamil, felodipine and losartan (for hypertension- high blood pressure)<br />□ Olaparib (used for treating ovarian cancer)<br />□ Ciclosporin, everolimus , sirolimus or tacrolimus (to prevent transplant rejection)<br />□ Cyclosphosphamide, vinca alkaloids (vincristine, vinblastine or similar medicines) used for treating cancer<br />□ Halofantrine (used for treating malaria)<br />□ Statins (atorvastatin, simvastatin and fluvastatin or similar medicines) used for reducing &nbsp;high cholesterol levels<br />□ Methadone (used for pain)<br />□ Celecoxib, flurbiprofen, naproxen, ibuprofen, lornoxicam, meloxicam, diclofenac (Non-Steroidal Anti-Inflammatory Drugs (NSAID))<br />□ Oral contraceptives &nbsp; &nbsp;<br />□ Prednisone (steroid)<br />□ Zidovudine, also known as AZT; saquinavir (used in HIV-infected patients)<br />□ Medicines for diabetes such as chlorpropamide, glibenclamide, glipizide or tolbutamide &nbsp;<br />□ Theophylline (used to control asthma)<br />□ Tofacitinib (used for treating rheumatoid arthritis)<br />□ Vitamin A (nutritional supplement)<br />□ Ivacaftor (used for treating cystic fibrosis)<br />□ Amiodarone (used for treating uneven heartbeats &lsquo;arrhythmias&rsquo;).<br />□ Hydrochlorothiazide (a diuretic)<br />□ Ibrutinib (used for treating blood cancer)<br />□ Lurasidone (used to treat schizophrenia)<br />Taking FUNZOL with food and drink:<br />You can take your medicine with or without a meal.&nbsp;<br />Pregnancy and breast-feeding:<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.&nbsp;<br />You should not take FUNZOL if you are pregnant, think you may be pregnant, are trying to become pregnant, unless your doctor has told you so. If you become pregnant while taking this medicine or within 1 week of the most recent dose, contact your doctor.<br />Fluconazole taken during the first trimester of pregnancy may increase the risk of miscarriage. Fluconazole taken at low doses during the first trimester may slightly increase the risk of a baby being born with birth defects affecting the bones and/or muscles.<br />You can continue breast-feeding after taking a single dose of FUNZOL 150 mg.&nbsp;<br />You should not breast-feed if you are taking a repeated dose of FUNZOL. &nbsp;<br />Driving and using machines:<br />When driving vehicles or using machines, it should be taken into account that occasionally dizziness or fits may occur.<br />Important information about some of the ingredients of FUNZOL:<br />This medicine contains a small amount of lactose (milk sugar). If you have been told by your doctor that you have an intolerance to some sugars, please contact your doctor before taking this medicine.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take your medicine exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.<br />Swallow the capsule whole with a glass of water. It is best to take your capsules at the same time each day.<br />The recommended doses of this medicine for different infections are below:<br />Adult:<br />□ To treat cryptococcal meningitis:<br />400 mg on the first day then 200 mg to 400 mg once daily for 6 to 8 weeks or longer if needed. Sometimes doses are increased up to 800 mg.<br />□ To stop cryptococcal meningitis from coming back:&nbsp;<br />200 mg once daily until you are told to stop.<br />□ To treat coccidioidomycosis: &nbsp;&nbsp;<br />200 mg to 400 mg once daily from 11 months for up to 24 months or longer if needed. Sometimes doses are increased up to 800 mg.<br />□ To treat internal fungal infections caused by Candida:<br />800 mg on the first day then 400 mg once daily until you are told to stop.<br />□ To treat mucosal infections affecting the lining of &nbsp;mouth, throat and denture sore mouth:<br />200 mg to 400 mg on the first day then 100 mg to 200 mg once daily until you are told to stop.<br />□ To treat mucosal thrush dose, depends on where the infection is located:<br />50 mg to 400 mg once daily for 7 to 30 days until you are told to stop.<br />□ To stop mucosal infections affecting the lining of mouth, throat from coming back:<br />100 mg to 200 mg once daily, or 200 mg 3 times a week, while you are at risk of getting an infection.<br />□ To treat genital thrush:<br />150 mg as a single dose.<br />□ To reduce recurrence of vaginal thrush:<br />150 mg every third day for a total of 3 doses (day 1, 4 and 7) and then once a week for 6 months while you are at risk of getting an infection.<br />□ To treat fungal skin and nail infections:<br />Depending on the site of the infection 50 mg once daily, 150 mg once weekly, 300 to 400 mg once weekly for 1 to 4 weeks (Athlete&rsquo;s foot may be up to 6 weeks, for nail infection treatment until infected nail is replaced).<br />□ To stop you from getting an infection caused by Candida, (if your immune system is weak and not working properly):<br />200 mg to 400 mg once daily while you are at risk of getting an infection.<br />Adolescents from 12 to 17 years old:<br />Follow the dose prescribed by your doctor (either adults or children posology).<br />Children to 11 years old:<br />The maximum dose for children is 400 mg daily.<br />The dose will be based on the child&rsquo;s weight in kilograms.<br />□ Mucosal thrush and throat infections caused by Candida, dose and duration depends on the severity of the infection and on where the infection is located:<br />3 mg per kg of body weight once daily (6 mg per kg of body weight might be given on the first day).<br />□ Cryptococcal meningitis or internal fungal infections caused by Candida:&nbsp;<br />6 mg to 12 mg per kg of body weight once daily.<br />□ To stop cryptococcal meningitis from coming back:&nbsp;<br />6 mg per kg of body weight once daily.<br />□ To stop children from getting an infection caused by Candida, (if their immune system is not working properly):<br />3 mg to 12 mg per kg of body weight once daily.<br />Use in children 0 to 4 weeks of age:<br />□ Use in children of 3 to 4 weeks of age:<br />The same dose as above but given once every 2 days. The maximum dose is 12 mg per kg of body weight every 48 hours.<br />□ Use in children less than 2 weeks old:<br />The same dose as above but given once every 3 days. The maximum dose is 12 mg per kg of body weight every 72 hours.<br />Elderly:<br />The usual adult dose should be given unless you have kidney problems.<br />Patients with kidney problems:<br />Your doctor may change your dose, depending on your kidney function.<br />If you take more FUNZOL than you should:<br />Taking too many capsules at once may make you unwell. Contact your doctor or your nearest hospital casualty department at once. The symptoms of a possible overdose may include hearing, seeing, feeling and thinking things that are not real (hallucination and paranoid behaviour).<br />Symptomatic treatment (with supportive measures and gastric lavage if necessary) may be adequate.&nbsp;<br />If you forget to take FUNZOL:<br />Do not take a double dose to make up for a forgotten dose. If you forget to take a dose, take it as soon as you remember. If it is almost time for your next dose, do not take the dose that you missed.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />Stop taking FUNZOL and seek medical attention immediately if you notice any of the following symptoms:<br />□ Widespread rash, high body temperature and enlarged lymph nodes (DRESS syndrome or drug hypersensitivity syndrome)<br />A few people develop allergic reactions although serious allergic reactions are rare. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. If you get any of the following symptoms, tell your doctor immediately.<br />□ Sudden wheezing, difficulty in breathing or tightness in the chest<br />□ Swelling of eyelids, face or lips &nbsp;&nbsp;<br />□ Itching all over the body, reddening of the skin or itchy red spots<br />□ Skin rash &nbsp;&nbsp;<br />□ Severe skin reactions such as a rash that causes blistering (this can affect the mouth and tongue).<br />Funzol may affect your liver. The signs of liver problems include:<br />□ Tiredness &nbsp;&nbsp;<br />□ Loss of appetite &nbsp;&nbsp;<br />□ Vomiting<br />□ Yellowing of your skin or the whites of your eyes (jaundice)<br />If any of these happen, stop taking FUNZOL and tell your doctor immediately.<br />Other side effects:<br />Additionally, if any of the following side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.<br />Common side effects (may affect up to 1 in 10 people) are:<br />□ Headache &nbsp;&nbsp;<br />□ Stomach discomfort, diarrhoea, feeling sick, vomiting<br />□ Increases in blood tests of liver function &nbsp; &nbsp;<br />□ Rash<br />Uncommon side effects (may affect up to 1 in 100 people) are:<br />□ Reduction in red blood cells which can make skin pale and cause weakness or &nbsp;breathlessness&nbsp;<br />□ Decreased appetite &nbsp;&nbsp;<br />□ Inability to sleep, feeling drowsy<br />□ Fit, dizziness, sensation of spinning, tingling, pricking or numbness, changes in sense of taste<br />□ Constipation, difficult digestion, wind, dry mouth<br />□ Muscle pain &nbsp;&nbsp;<br />□ Liver damage and yellowing of the skin and eyes (jaundice)<br />□ Wheals, blistering (hives), itching, increased sweating &nbsp;&nbsp;<br />□ Tiredness, general feeling of being unwell, fever<br />Rare side effects (may affect up to 1 in 1,000 people) are:<br />□ Lower than normal white blood cells that help defend against infections and blood cells that help to stop bleeding&nbsp;<br />□ Red or purple discoloration of the skin which may be caused by low platelet count, other blood cell changes<br />□ Blood chemistry changes (high blood levels of cholesterol, fats)<br />□ Low blood potassium &nbsp; &nbsp;&nbsp;<br />□ Shaking<br />□ Abnormal electrocardiogram (ECG), change in heart rate or rhythm &nbsp;&nbsp;<br />□ Liver failure<br />□ Allergic reactions (sometimes severe), including widespread blistering rash and skin peeling, severe skin reactions, swelling of the lips or face &nbsp; &nbsp;<br />□ Hair loss<br />Frequency not known, but may occur (cannot be estimated from the available data):<br />- Hypersensitivity reaction with skin rash, fever, swollen glands, increase in a type of white blood cell (eosinophilia) and inflammation of internal organs (liver, lungs, heart, kidneys and large intestine) (Drug Reaction or rash with Eosinophilia and Systemic Symptoms (DRESS))<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />□ Do not store above 30&deg;C, protected from humidity.&nbsp;<br />□ Do not use FUNZOL after the expiry date which is stated on the carton and on the blister, after (EXP).Date.<br />Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Fluconazole. Each FUNZOL Capsule contains 150 mg of the active ingredient Fluconazole.<br />□ The other ingredients are: Lactose D.C., sodium starch glycolate type A, sodium lauryl sulphate, colloidal anhydrous silica, magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                FUNZOL 150 Capsules are cylindrical hard gelatin capsule of size 1 composed of blue clear body printed with Funzol   and blue clear cap printed with 150 mg filled with white powder.
□ Boxes of one blistered capsule of FUNZOL 150.
□ Boxes of 168 blistered capsule of FUNZOL 150.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Jordanian pharmaceutical manufacturing company.</p><p>P.O. BOX 151, Um Al-Amad 16197, Jordan<br />Saudi Arabia: To report any side effect(s):&nbsp;<br />The National Pharmacovigilance Center (NPC):<br />Fax: +966-11-205-7662,<br />SFDA Call Center: 19999,<br />E-mail: npc.drug@sfda.gov.sa,<br />Website: http://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                November 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ينتمي فنزول إلى مجموعة من الأدوية التي تدعى &quot;مضادات الفطريات&quot;. المادة الفعالة هي فلوكونازول.<br />يستخدم فنزول لعلاج الالتهابات التي تسببها الفطريات، ويمكن أن تستخدم أيضاً للوقاية من عدوى المبيضات.<br />&nbsp;أكثر مسبب للالتهابات الفطرية هي خميرة تدعى المبيضات.<br />البالغين:<br />قد يتم وصف هذا الدواء من قبل الطبيب لعلاج الأنواع التالية من االعدوى الفطرية:<br />□ التهاب السحايا بالمستخفيات - التهاب فطري في الدماغ.<br />□ الفطار الكرواني - وهو مرض يصيب الجهاز التنفسي.<br />□ العدوى التي تسببها المبيضات والموجودة في مجرى الدم، وأعضاء الجسم (مثل القلب والرئتين) أو المسالك البولية.<br />□ السلاق المخاطي: العدوى التي تؤثر على بطانة الفم والحلق وقرحة البدلة السنية.<br />□ السلاق التناسلي: عدوى المهبل أو القضيب.<br />□ عدوى الجلد: على سبيل المثال القدم الرياضي، سعفة، حكة اللعب، عدوى الأظافر .<br />يمكن استخدام فنزول في الحالات التالية أيضاَ:<br />□ منع تكرار الإصابة بالتهاب السحايا بالمستخفيات.<br />□ منع تكرار الإصابة بالسلاق المخاطية.<br />□ الحد من تكرار الإصابة بالسلاق المهبلي.<br />□ الوقاية من الإصابة بالعدوى التي تسببها المبيضات (إذا كان الجهاز المناعي ضعيف ولا يعمل بشكل صحيح).<br />الأطفال والمراهقين (الذين &nbsp;تتراوح أعمارهم من يوم إلى 17 سنة):<br />قد يتم وصف هذا الدواء من قبل الطبيب لعلاج الأنواع التالية من الالتهابات الفطرية:<br />□ السلاق المخاطي: عدوى تؤثر على بطانة الفم والحلق&nbsp;<br />□ العدوى التي تسببها المبيضات والموجودة في مجرى الدم، وأعضاء الجسم (مثل القلب والرئتين) أو المسالك البولية<br />□ &nbsp;التهاب السحايا بالمستخفيات - التهاب فطري في الدماغ<br />يمكن استخدام فنزول في الحالات التالية أيضاَ:<br />□ الوقاية من الإصابة بالعدوى التي تسببها المبيضات (إذا كان الجهاز المناعي ضعيف ولا يعمل بشكل صحيح).<br />□ منع تكرار الإصابة بالتهاب السحايا بالمستخفيات.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>□ إذا كنت تعاني من حساسية لفلوكونازول أو للأدوية الأخرى التي تؤخذ لعلاج العدوى الفطرية أو لأي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6). و قد تشمل الأعراض مثل الحكة، احمرار الجلد أو صعوبة التنفس.<br />□ إذا كنت تتناول استيميزول، تيرفينادين (مضادات الهستامين لعلاج الحساسية).<br />□ إذا كنت تتناول سيسابرايد (يستخدم لعلاج اضطراب المعدة).<br />□ إذا كنت تتناول بيموزايد (يستخدم لعلاج الأمراض العقلية).<br />□ إذا كنت تتناول كوانيدين (يستخدم لعلاج عدم انتظام ضربات القلب).<br />□ إذا كنت تتناول إريثرومايسين (مضاد حيوي لعلاج العدوى).<br />الاحتياطات عند استعمال فنزول:<br />تحدث إلى طبيبك أو الصيدلي قبل تناول فنزول:<br />□ إذا كنت تعاني من اضطرابات في الكبد أو الكلى.<br />□ إذا كنت تعاني من أمراض القلب، بما في ذلك عدم انتظام ضربات القلب.<br />□ إذا كان لديك مستويات غير طبيعية من البوتاسيوم، الكالسيوم أو المغنيسيوم في الدم.<br />□ إذا عانيت من تفاعلات جلدية حادة (حكة، احمرار في الجلد أو صعوبة في التنفس).<br />□ إذا عانيت من علامات &lsquo;قصور الغدة الكظرية&rsquo; حيث أن الغدد الكظرية لا تنتج كميات كافية من بعض هرمونات الستيرويد مثل كورتيزول (مزمن، تعب طويل الأمد، ضعف في العضلات، فقدان الشهية، فقدان الوزن، ألم في البطن).<br />□ إذا كنت قد أصبت في أي وقت مضى بطفح جلدي شديد أو تقشير جلدي، ظهور بثور و/ أو تقرحات في الفم بعد تناول فلوكونازول<br />تم الإبلاغ عن تفاعلات جلدية خطيرة بما في ذلك تفاعل دوائي مع فرط الخلايا اليوزينية والأعراض الجهازية (DRESS) بالتزامن مع العلاج باستخدام فلوكونازول. توقف عن تناول فنزول واطلب العناية الطبية على الفور إذا لاحظت أيًا من الأعراض المتعلقة بتفاعلات الجلد الخطيرة الموضحة في القسم 4.<br />تحدث إلى طبيبك أو الصيدلي إذا لم تتحسن العدوى الفطرية ، فقد تكون هناك حاجة إلى علاج بديل مضاد للفطريات.<br />تناول فنزول مع أدوية أخرى:<br />أخبر طبيبك أو الصيدلاني المسؤول إذا كنت تتناول، &nbsp;تناولت مؤخراً أو قد تتناول أي أدوية اخرى.<br />أخبر طبيبك على الفور إذا كنت تتناول استيميزول، تيرفينادين (مضاد للهستامين لعلاج الحساسية)، سيسابرايد (يستخدم لعلاج اضطراب المعدة)، بيموزايد (يستخدم لعلاج الأمراض العقلية)، الكوانيدين (يستخدم لعلاج عدم انتظام ضربات القلب) أو الاريثرومايسين (مضاد حيوي لعلاج العدوى) حيث لا ينبغي تناول هذه الأدوية مع فنزول (انظر إلى قسم: موانع استعمال فنزول).<br />هناك بعض الأدوية التي قد تتفاعل مع فنزول. تأكد من أن طبيبك يعرف ما إذا كنت تتناول أيًا من الأدوية التالية حيث قد يكون هناك الحاجة لتعديل الجرعة أو مراقبة تأثير الدواء للتحقق من أن الأدوية لا تزال تحقق التأثير المطلوب:<br />□ ريفامبيسين أو ريفابيوتين (مضادات حيوية تستخدم لعلاج العدوى).<br />□ أبروكيتنيب (يستخدم لعلاج التهاب الجلد التأتبي، والتي تعرف أيضا بالإكزيما التأتبية).<br />□ ألفينتانيل، فنتانيل (يستخدم كمخدر).<br />□ أميتريبتيلين، نورتريبتيلين (تستخدم كمضادات للاكتئاب).<br />□ أمفوتريسين ب، فوريكونازول (مضاد للفطريات).<br />□ الأدوية المميعة للدم والتي تستخدم لمنع التجلطات (الوارفارين أو الأدوية المشابهة له).<br />□ بنزوديازيبين (ميدازولام، تريازولام أو الأدوية المشابهة) تستخدم للمساعدة على النوم أو للقلق.<br />□ كاربامازيبين، فينيتوين (التي تستخدم لعلاج النوبات).<br />□ نيفيديبين، إسراديبين، أملوديبين، فيراباميل، فيلوديبين والوسارتان (لعلاج ارتفاع ضغط الدم).<br />□ أولاباريب (يستخدم لعلاج سرطان المبايض)<br />□ سيكلوسبورين، ايفيروليموس، سيروليمس أو تاكروليماس (مثبطات المناعة لمنع رفض الأعضاء المزروعة من قبل الجسم).<br />□ سيكلوفوسفاميد، قلوانيات الفينكا (فينكريستين، فينبلاستين أو الأدوية المشابهة) المستخدمة لعلاج السرطان.<br />□ هالوفانترين (يستخدم لعلاج الملاريا).<br />□ ستاتين (أتورفاستاتين، سيمفاستاتين وفلوفاستاتين أو الأدوية المشابهة) تستخدم لخفض مستويات الكولسترول المرتفعة في الدم.<br />□ ميثادون (مسكن الآلام).<br />□ سيليكوكسيب، فلوربيبروفين، نابروكسين، أيبوبروفين، لورنوكسيكام، ميلوكسيكام، ديكلوفيناك (مضادات &nbsp;الالتهاب غير الستيرويدية).<br />□ موانع الحمل التي تؤخذ عن طريق الفم. &nbsp; &nbsp;<br />□ بريدنيزون (الستيرويد).<br />□ زيدوفودين، المعروف أيضا باسم &quot;أزت&quot; ساكوينافير (التي تستخدم لعلاج المرضى المصابين بفيروس نقص المناعة).<br />□ &nbsp;أدوية السكري مثل كلوربروباميد، غليبينكلامايد، غليبيزايد أو تولبيوتاميد.<br />□ &nbsp;ثيوفيلين (يستخدم للسيطرة على الربو). &nbsp; &nbsp;&nbsp;<br />□ توفاكتينيب (يستخدم لعلاج التهاب المفاصل الروماتيدي)<br />□ &nbsp;فيتامين (أ) (مكمل غذائي). &nbsp; &nbsp;<br />□ إيفاكافتور (التي تستخدم لعلاج التليف الكيسي).<br />□ أميودارون (يستخدم لعلاج عدم انتظام ضربات القلب) &nbsp; □ هايدروكلوروثايزيد (مدر بول) &nbsp; &nbsp;&nbsp;<br />□ ابروتينيب (يستخدم لعلاج سرطان الدم)<br />□ لوراسيدون (يستخدم لعلاج الفصام)<br />تناول فنزول مع الطعام &nbsp;والشراب:<br />يمكن تناول دوائك مع الطعام أو بدونه.<br />الحمل والرضاعة:<br />إذا كنت حامل أو مرضعة أو من المحتمل أن تصبحي حاملاً، استشر طبيبك أو الصيدلي قبل أخذ الدواء.<br />يجب عليكِ عدم أخذ فنزول إذا كنتِ حاملاً، تعتقدين أنك حامل، تحاولين الحمل، ما لم يخبرك طبيبك بذلك. إذا أصبحت حاملاً أثناء تناول هذا الدواء أو في غضون أسبوع واحد من أحدث جرعة، فاتصلي بطبيبك.<br />قد يؤدي تناول فلوكونازول خلال الأشهر الثلاثة الأولى من الحمل إلى زيادة خطر الإجهاض. قد يؤدي تناول فلوكونازول بجرعات منخفضة خلال الأشهر الثلاثة الأولى من الحمل إلى زيادة طفيفة في خطر ولادة طفل بعيوب خلقية تؤثر على العظام و/ أو العضلات.<br />يمكنك الاستمرار في الرضاعة الطبيعية بعد أخذ جرعة واحدة من فنزول تصل الى 150 ملغم.<br />لا ينبغي الاستمرار في الإرضاع إذا كنت تتناولين جرعات متكررة من فنزول.<br />تأثير فنزول على القيادة واستخدام الآلات:<br />عند القيادة أو استخدام الآلات، فإنه ينبغي أن يؤخذ في الاعتبار بأن فنزول &nbsp;قد يسبب دوخة أو نوبة.<br />معلومات هامة حول بعض مكونات فنزول:<br />يحتوي فنزول على كمية صغيرة من لاكتوز (سكرالحليب). إذا أخبرك طبيبك بأنك لا تستطيع تحمل بعض أنواع السكريات، فإنه يجب عليك استشارة طبيبك قبل تناول هذا الدواء.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب عليك أن تتناول الدواء تماماً كما أخبرك طبيبك. &nbsp;يجب عليك مراجعة طبيبك أو الصيدلي إذا لم تكن متأكداً.<br />ابتلع الكبسولة كاملة مع كوب من الماء، من الأفضل تناول الكبسولة في نفس الوقت من كل يوم.<br />الجرعات الموصى بها &nbsp;من هذا الدواء لعلاج أنواع العدوى التالية:<br />البالغين:<br />□ &nbsp;لعلاج التهاب السحايا بالمستخفيات:<br />400 ملغم في اليوم الأول ثم 200 ملغم إلى 400 ملغم مرة واحدة يومياً لمدة 6 إلى 8 أسابيع أو لمدة أطول إن لزم الأمر. يتم زيادة الجرعة في بعض الحالات إلى 800 ملغم.<br />□ منع تكرار الإصابة بالتهاب السحايا بالمستخفيات:<br />200 ملغم مرة واحدة يومياً حتى يطلب منك طبيبك التوقف عن تناوله.<br />□ علاج الفطار الكرواني:<br />200 ملغم إلى 400 ملغم مرة واحدة يومياً لفترة تتراوح ما بين 11 شهر إلى 24 شهر أو أكثر إن لزم الأمر. يتم زيادة الجرعة في بعض الحالات إلى 800 ملغم.<br />□ علاج العدوى الداخلية التي تسببها المبيضات:<br />800 ملغم في اليوم الأول ثم 400 ملغم مرة واحدة يومياً إلى أن يطلب منك طبيبك التوقف عن تناوله.<br />□ علاج عدوى الغشاء المخاطي التي تؤثر على بطانة الفم والحلق وقرحة البدلة السنية:<br />200 ملغم إلى 400 ملغم في اليوم الأول ثم 100 ملغم إلى 200 ملغم مرة واحدة يومياً إلى أن يطلب منك &nbsp;طبيبك التوقف عن تناوله.<br />□ علاج السلاق المخاطي، &nbsp;تعتمد الجرعة على مكان العدوى:<br />50 ملغم إلى 400 ملغم مرة واحدة يومياً لمدة تتراوح ما بين 7 إلى 30 يوم حتى يطلب منك الطبيب التوقف عن تناوله.<br />□ لمنع عدوى الغشاء المخاطي التي تؤثر على بطانة الفم والحلق من العودة:<br />100 ملغم إلى 200 ملغم مرة واحدة يومياً، أو 200 ملغم 3 مرات في الأسبوع، إذا كنت عرضة للإصابة بالعدوى.<br />□ لعلاج السلاق التناسلي:<br />150 ملغم جرعة واحدة.<br />□ للحد من تكرار الإصابة بالسلاق المهبلي:<br />150 ملغم على 3 جرعات كل ثلاثة أيام على التوالي (اليوم الأول و الرابع و السابع) وبعد ذلك مرة واحدة في الأسبوع لمدة 6 أشهر إذا كنت عرضة للإصابة بالعدوى.<br />□ لعلاج العدوى الفطرية للجلد والأظافر:<br />اعتماداً على موقع الإصابة تكون الجرعة 50 ملغم مرة واحدة يومياً، 300 إلى 400 ملغم مرة واحدة أسبوعياً لفترة تتراوح ما بين أسبوع إلى أربعة أسابيع (لعلاج عدوى القدم الرياضي قد تصل مدة العلاج إلى 6 أسابيع، لعلاج عدوى الأظافر حتى يتم استبدال الأظفر المصاب)<br />□ لمنع الإصابة بالعدوى التي تسببها المبيضات (إذا كان الجهاز المناعي ضعيف ولا يؤدي وظيفته بشكل طبيعي):<br />200 ملغم إلى 400 ملغم مرة واحدة يومياً إذا كنت عرضة للإصابة بالعدوى.<br />المراهقين الذين تترواح أعمارهم ما بين 12 إلى 17 سنة:<br />اتبع الجرعة الموصوفة لك من قبل الطبيب ( إما جرعة البالغين أو الأطفال).<br />الأطفال الذين تترواح أعمارهم ما بين 11 سنة أو أقل:<br />الجرعة القصوى للأطفال هي 400 ملغم يومياً.<br />ستعتمد الجرعة على وزن الطفل بالكيلوغرام.<br />□ تعتمد الجرعة ومدة العلاج في حالة السلاق المخاطي و عدوى الحلق التي تسببها المبيضات على شدة الإصابة وعلى مكان الإصابة:<br />3 ملغم لكل كيلوغرام من وزن الجسم مرة واحدة يومياً (يمكن أن يعطى 6 ملغم لكل كيلوغرام من وزن الجسم في اليوم الأول).<br />□ التهاب السحايا بالمستخفيات أو عدوى الفطريات الداخلية التي تسببها المبيضات:<br />6 ملغم إلى 12 ملغم لكل كيلوغرام من وزن الجسم مرة واحدة يومياً.<br />□ لمنع التهاب السحايا بالمستخفيات من العودة مرة أخرى:<br />6 ملغم إلى 12 ملغم لكل كيلوغرام من وزن الجسم مرة واحدة يومياً.<br />□ للوقاية من الإصابة بالعدوى الفطرية &nbsp;التي تسببها المبيضات لدى الأطفال (إذا كان الجهاز المناعي ضعيف ولا يؤدي وظيفته بشكل طبيعي):<br />3 ملغم إلى 12 ملغم لكل كيلوغرام من وزن الجسم مرة واحدة يومياً.<br />الأطفال الذين تترواح أعمارهم من يوم إلى 4 أسابيع:<br />□ الاستعمال لدى للأطفال ( الذين تترواح أعمارهم من 3 إلى 4 أسابيع):<br />نفس الجرعة المذكورة أعلاه ولكن مرة واحدة كل يومين، الجرعة القصوى هي 12 ملغم لكل كيلوغرام من وزن المريض كل 48 ساعة.<br />□ الاستعمال لدى الأطفال ( الذين تقل أعمارهم عن أسبوعين):<br />نفس الجرعة المذكورة أعلاه ولكن مرة واحدة كل 3 أيام، الجرعة القصوى هي 12 ملغم لكل كيلوغرام من وزن المريض كل 72 ساعة.<br />كبار السن:<br />يعطى نفس الجرعة المعتادة للبالغين إلا إذا كان هناك مشاكل في الكلى.<br />المرضى الذين &nbsp;يعانون من أمراض في الكلى:<br />قد يقوم طبيبك بتعديل الجرعة اعتماداً على نتائج فحوصات &nbsp;وظائف الكلى الخاصة بك.<br />الجرعة الزائدة من فنزول:&nbsp;<br />قد تصاب بتوعك عند تناولك الكثير من الكبسولات &nbsp;دفعة واحدة، يجب عليك الاتصال بطبيبك أو الذهاب إلى أقرب مستشفى على الفور. &nbsp;قد تشمل أعراض الجرعة الزائدة السمع، البصر، الشعور والتفكير بأشياء غير موجودة على أرض الواقع (هلوسة والسلوك بارانويدي).<br />قد يكون علاج الأعراض كافي (التدابير الداعمة وغسل المعدة إذا لزم الأمر).<br />نسيان تناول جرعة فنزول:<br />لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية. في حال نسيانك تناول الجرعة، فإنه يجب عليك تناولها عند تذكرها، و إذا كان وقت الجرعة التالية قد اقترب، فإنه يجب عليك تخطي الجرعة المنسية.<br />إذا كانت لديك أي استفسارات أخرى عن استخدام هذا الدواء، اسأل طبيبك أو الصيدلي .<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كغيره من الأدوية، فقد يسبب فنزول أعراضاً جانبيةً، بالرغم من أنها لا تحدث للجميع.<br />توقف عن تناول فنزول واطلب العناية الطبية فورًا إذا لاحظت أيًا من الأعراض التالية:<br />□ طفح جلدي واسع الانتشار، ارتفاع درجة حرارة الجسم وتضخم الغدد الليمفاوية (متلازمة DRESS أو متلازمة فرط الحساسية للأدوية)<br />عدد قليل من الناس يصابون بالحساسية على الرغم من حدوث أعراض حساسية خطيرة نادر. اذا حدث لك أياً من الأعراض الجانبية هذه، فإنه يجب عليك التحدث لطبيبك أو الصيدلي، وهذا يشمل أي أعراض جانبية غير المدرجة في هذه النشرة. اذا حدتث لديك أي من الأعراض التالية، أخبر طبيبك على الفور:<br />□ أزيز مفاجئ، وصعوبة في التنفس أو ضيق في الصدر. &nbsp; &nbsp;□ تورم الجفون، الوجه أو الشفتين.<br />□ حكة في جميع أنحاء الجسم، واحمرار الجلد أو ظهور بقع حمراء على الجلد.<br />□ طفح جلدي. &nbsp; &nbsp;<br />□ تفاعلات جلدية حادة مثل الطفح الجلدي الذي يسبب تقرحات (يمكن أن يؤثر على الفم واللسان).<br />قد يؤثر الفلوكونازول على الكبد، و أعراض هذا الاضطراب الكبدي تشمل:<br />□ التعب &nbsp; &nbsp;<br />□ فقدان الشهية<br />□ القيء &nbsp; &nbsp;<br />□ اصفرار الجلد أو بياض العينين (اليرقان)<br />&nbsp;إذا كانت لديك أي من هذه الأعراض، توقف عن &nbsp;تناول فنزول واتصل بطبيبك على الفور<br />أعراض جانبية أخرى:<br />بالإضافة إلى ذلك، إذا كان أي من الآثار الجانبية التالية أصبحت خطيرة، أو إذا لاحظت أي آثار جانبية غير مدرجة في هذه النشرة، يرجى إخبار طبيبك أو الصيدلي.<br />أعراض جانبية شائعة (قد تؤثرعلى ما يصل إلى شخص واحد من كل عشرة أشخاص):<br />□ صداع &nbsp; &nbsp;<br />□ اضطراب في المعدة ، إسهال، والشعور بالغثيان والقيء<br />□ ارتفاع &nbsp;نتائج فحوصات وظائف الكبد في الدم &nbsp; &nbsp;<br />□ طفح جلدي<br />أعراض جانبية غير شائعة (قد تؤثر على ما يصل إلى شخص واحد من كل 100 شخص):<br />□ انخفاض في خلايا الدم الحمراء الذي قد يسبب شحوب وضعف أو ضيق في التنفس<br />□ فقدان الشهية<br />□ عدم القدرة على النوم، والشعور بالنعاس<br />□ نوبات، دوخة، الإحساس بالدوران، وخز وخدران، وتغييرات في حاسة التذوق<br />□ إمساك، صعوبة في الهضم، ريح، وجفاف الفم &nbsp; &nbsp;<br />□ ألم في العضلات<br />□ تلف الكبد واصفرار في الجلد والعينين (اليرقان) &nbsp; &nbsp;<br />□ شرى، تقرحات، حكة، وزيادة في التعرق<br />□ تعب، الشعور العام بتوعك وحمى<br />الأعراض الجانبية النادرة (قد تؤثر على ما يصل إلى شخص واحد &nbsp;من كل 1000 شخص):<br />□ انخفاض خلايا الدم البيضاء التي تساعد في الدفاع ضد &nbsp;العدوى وخلايا الدم التي تساعد على وقف النزيف<br />□ تغير لون الجلد إلى الأحمر أو الأرجواني الناجم عن انخفاض في عدد الصفائح الدموية، تغير في خلايا الدم الأخرى<br />□ تغير في فحوصات الدم (ارتفاع مستويات الكوليسترول والدهون في الدم)<br />□ انخفاض مستوى البوتاسيوم في الدم &nbsp;&nbsp;<br />□ ارتعاش<br />□ تغير في مخطط كهربائية القلب، وتغير في معدل ضربات القلب أو في نظم القلب &nbsp; &nbsp;<br />□ فشل الكبد<br />□ تفاعلات تحسسيية (تكون حادة في بعض الحالات)، تشمل طفح جلدي متقرح على نطاق واسع &nbsp;من الجلد، تقشر الجلد، اضطربات جلدية شديدة، تورم الشفتين أو الوجه<br />□ تساقط الشعر<br />أعراض جانبية غير معروفة، لكن قد تحدث (لا يمكن تقديرها من البيانات المتاحة):<br />- تفاعل فرط الحساسية مع طفح جلدي، حمى، تورم الغدد، زيادة نوع من خلايا الدم البيضاء (فرط الخلايا االيوزينية) والتهاب الأعضاء الداخلية (الكبد، الرئتين، القلب، الكلى والأمعاء الغليظة) (تفاعل دوائي أو طفح جلدي مع فرط الخلايا اليوزينية والأعراض الجهازية (DRESS))<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;يحفظ بعيداً عن متناول الأطفال.&nbsp;<br />□ لا يحفظ بدرجة حرارة أعلى من 30&deg;م ، يحفظ بعيداً عن الرطوبة.&nbsp;<br />□ لا ينبغي استعمال فنزول بعد تاريخ انتهاء الصلاحية الموجود على العلبة وعلى شريط الدواء.&nbsp;<br />لا ينبغي التخلص من الأدوية من خلال مياه الصرف الصحي أو المنزلي. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. سوف تساعد هذه الاجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي فلوكونازول، كل كبسولة من فنزول تحتوي على 150 ملغم &nbsp;فلوكونازول.<br />المكونات الأخرى هي: لاكتوز، جلايكولات نشا الصوديوم نوع أ، كبريتات لوريل الصوديوم، سيليكا غروية لامائية، ستيارات المغنيزيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;كبسولات فنزول 150 هي كبسولات جيلاتينية صلبة، اسطوانية الشكل من حجم 1 تتكون من جسم أزرق واضح مطبوع عليه &nbsp;&reg;Funzol وغطاء أزرق اللون شفاف مطبوع عليه 150mg ، مملوءة بمسحوق أبيض اللون.<br />□ علب تحتوي على كبسولة واحدة من فنزول 150 المحفوظة في أشرطة.<br />□علب تحتوي على 168 كبسولة من فنزول 150 المحفوظة في أشرطة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الشركة الأردنية لإنتاج الأدوية. ص.ب. 151 - أم العمد 16197 - الأردن.</p><p>المملكة العربية السعودية: للإبلاغ عن الأعراض الجانبية:<br />المركز الوطني للتيقظ الدوائي:&nbsp;<br />فاكس: 966112057662 +،&nbsp;<br />مركز الاتصال بالهيئة العامة للغذاء و الدواء في السعودية: 19999، البريد الإلكتروني: Npc.drug@sfda.gov.sa<br />الموقع الإلكتروني:&nbsp;<br />https://ade.sfda.gov.sa</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تشرين الثاني 2023.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                FUNZOL 150 Capsules.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active ingredient:
 Fluconazole 150 mg.
Inactive ingredients:
Ingredient Quantity
mg/cap.
Lactose D.C. 126.0
 Sodium Starch Glycollate 12.0
 Sodium Lauryl Sulphate 6.0
 Colloidal Anhydrous Silica 3.0
 Magnesium Stearate 3.0
 *For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cylindrical Hard gelatin capsule composed of blue clear body and blue clear cap or 
blue clear body printed with Funzol® and blue clear cap printed with 150 mg filled 
with white powder.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>FUNZOL is indicated in the following fungal infections (see section 5.1). FUNZOL is indicated in adults for the treatment of: ▪ Cryptococcal meningitis (see section 4.4). ▪ Coccidioidomycosis (see section 4.4). SPC FUNZOL 150 mg CAPSULES ▪ Invasive candidiasis. ▪ Mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis. ▪ Chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient. ▪ Vaginal candidiasis, acute or recurrent; when local therapy is not appropriate. ▪ Candidal balanitis when local therapy is not appropriate. ▪ Dermatomycosis including tinea pedis, tinea corporis, tinea cruris, tinea versicolor and dermal candida infections when systemic therapy is indicated. ▪ Tinea unguinium (onychomycosis) when other agents are not considered appropriate. FUNZOL is indicated in adults for the prophylaxis of: ▪ Relapse of cryptococcal meningitis in patients with high risk of recurrence. ▪ Relapse of oropharyngeal or oesophageal candidiasis in patients infected with HIV who are at high risk of experiencing relapse. ▪ To reduce the incidence of recurrent vaginal candidiasis (4 or more episodes a year). ▪ Prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving Hematopoietic Stem Cell Transplantation (see section 5.1)). FUNZOL is indicated in term newborn infants, infants, toddlers, children, and adolescents aged from 0 to 17 years old: FUNZOL is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis, cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. FUNZOL can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence (see section 4.4). Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. Consideration should be given to official guidance on the appropriate use of antifungals. SPC FUNZOL 150 mg CAPSULE</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Route of administration: Oral Posology The dose should be based on the nature and severity of the fungal infection. Treatment of infections requiring multiple dosing should be continued until clinical parameters or laboratory tests indicate that active fungal infection has subsided. An inadequate period of treatment may lead to recurrence of active infection. Adults: Indications Posology Duration of treatment Cryptococcosis Treatment of cryptococcal meningitis. Loading dose: 400 mg on Day 1 Subsequent dose: 200 mg to 400 mg daily Usually at least 6 to 8 weeks. In life threatening infections the daily dose can be increased to 800 mg Maintenance therapy to prevent relapse of cryptococcal meningitis in patients with high risk of recurrence. 200 mg daily Indefinitely at a daily dose of 200 mg Coccidioidomycosis 200 mg to 400 mg once daily 11 months up to 24 months or longer depending on the patient. 800 mg daily may be considered for some infections and especially for meningeal disease Invasive candidiasis Loading dose: 800 mg on Day 1 Subsequent dose: 400 mg once daily In general, the recommended duration of therapy for candidemia is for 2 weeks after first negative blood culture result and resolution of signs and symptoms attributable to candidemia. Treatment of mucosal candidiasis Oropharyngeal candidiasis Loading dose: 200 mg to 400 mg on 7 to 21 days (until oropharyngeal candidiasis is in SPC FUNZOL 150 mg CAPSULES Indications Posology Duration of treatment Day 1 Subsequent dose: 100 mg to 200 mg once daily remission). Longer periods may be used in patients with severely compromised immune function Oesophageal candidiasis Loading dose: 200 mg to 400 mg on Day 1 Subsequent dose: 100 mg to 200 mg once daily 14 to 30 days (until oesophageal candidiasis is in remission). Longer periods may be used in patients with severely compromised immune function Candiduria 200 mg to 400 mg once daily 7 to 21 days. Longer periods may be used in patients with severely compromised immune function Chronic atrophic candidiasis 50 mg daily 14 days Chronic mucocutaneous candidiasis 50 mg to 100 mg daily Up to 28 days. Longer periods depending on both the severity of infection or underlying immune compromisation and infection Prevention of relapse of mucosal candidiasis in patients infected with HIV who are at high risk of experiencing relapse Oropharyngeal candidiasis 100 mg to 200 mg daily or 200 mg 3 times per week An indefinite period for patients with chronic immune suppression Oesophageal candidiasis 100 mg to 200 mg daily or 200 mg 3 times per week An indefinite period for patients with chronic immune suppression Genital candidiasis Acute vaginal candidiasis Candidal balanitis 150 mg Single dose Treatment and 150 mg every third Maintenance dose: 6 SPC FUNZOL 150 mg CAPSULES Indications Posology Duration of treatment prophylaxis of recurrent vaginal candidiasis (4 or more episodes a year). day for a total of 3 doses (day 1, 4, and 7) followed by 150 mg once weekly maintenance dose months. Dermatomycosis tinea pedis, tinea corporis, tinea cruris, candida infections 150 mg once weekly or 50 mg once daily 2 to 4 weeks, tinea pedis may require treatment for up to 6 weeks tinea versicolor 300 mg to 400 mg once weekly 1 to 3 weeks 50 mg once daily 2 to 4 weeks tinea unguium (onychomycosis) 150 mg once weekly Treatment should be continued until infected nail is replaced (uninfected nail grows in). Regrowth of fingernails and toenails normally requires 3 to 6 months and 6 to 12 months, respectively. However, growth rates may vary widely in individuals, and by age. After successful treatment of longterm chronic infections, nails occasionally remain disfigured. Prophylaxis of candidal infections in patients with prolonged neutropenia 200 mg to 400 mg once daily Treatment should start several days before the anticipated onset of neutropenia and continue for 7 days after recovery from neutropenia after the neutrophil count rises above 1000 cells per mm3 SPC FUNZOL 150 mg CAPSULES Special populations Elderly Dosage should be adjusted based on the renal function (see &ldquo;Renal impairment&rdquo;). Renal impairment Funzol is predominantly execreted in the urine as unchanged active substance. No adjustments in single dose therapy are necessary. In patients (including paediatric population) with impaired renal function who will receive multiple doses of fluconazole, an initial dose of 50 mg to 400 mg should be given, based on the recommended daily dose for the indication. After this initial loading dose, the daily dose (according to indication) should be based on the following table: Creatinine clearance (ml/min) Percent of recommended dose &gt;50 100% &le;50 (no dialysis) 50% Haemodialysis 100% after each heamodialysis Patients on heamodialysis should receive 100% of the recommended dose after each dialysis; on non-dialysis days, patients should receive a reduced dose according to their creatinine clearance. Hepatic impairment Limited data are available in patients with hepatic impairment; therefore, fluconazole should be administered with caution to patients with liver dysfunction (see sections 4.4 and 4.8). Paediatric population A maximum dose of 400 mg daily should not be exceeded in paediatric population. As with similar infections in adults, the duration of treatment is based on the clinical and mycological response. Fluconazole is administered as a single daily dose. For paediatric patients with impaired renal function, see dosing in &ldquo;Renal impairment&rdquo;. The pharmacokinetics of fluconazole has not been studied in paediatric population with renal insufficiency (for &ldquo;Term newborn infants&rdquo; who often exhibit primarily renal immaturity please see below). SPC FUNZOL 150 mg CAPSULES Infants, toddlers and children (from 28 days to 11 years old): Indication Posology Recommendations - Mucosal candidiasis Initial dose: 6 mg/kg Subsequent dose: 3 mg/kg once daily Initial dose may be used on the first day to achieve steady state levels more rapidly - Invasive candidiasis -Cryptococcal meningitis Dose: 6 to 12 once mg/kg daily Depending on the severity of the disease - Maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of recurrence Dose: 6 mg/kg once daily Depending on the severity of the disease - Prophylaxis of Candida in immunocompromised patients Dose: 3 to 12 mg/kg once daily Depending on the extent and duration of the induced neutropenia (see Adults posology) Adolescents (from 12 to 17 years old): Depending on the weight and pubertal development, the prescriber would need to assess which posology (adults or children) is the most appropriate. Clinical data indicate that children have a higher fluconazole clearance than observed for adults. A dose of 100, 200 and 400 mg in adults corresponds to a 3, 6 and 12 mg/kg dose in children to obtain a comparable systemic exposure. Safety and efficacy for genital candidiasis indication in paediatric population has not been established. Current available safety data for other paediatric indications are described in section 4.8. If treatment for genital candidiasis is imperative in adolescents (from 12 to 17 years old), the posology should be the same as adult&rsquo;s posology. SPC FUNZOL 150 mg CAPSULES Term newborn infants (0 to 27 days): Neonates excrete fluconazole slowly. There are few pharmacokinetic data to support this posology in term newborn infants (see section 5.2). Age group Posology Recommendations Term newborn infants (0 to 14 days) The same mg/kg dose as for infants, toddlers and children should be given every 72 hours A maximum dose of 12 mg/kg every 72 hours should not be exceeded Term newborn infants (from 15 to 27 days) The same mg/kg dose as for infants, toddlers and children should be given every 48 hours A maximum dose of 12 mg/kg every 48 hours should not be exceeded Method of administration Fluconazole may be administered either (Capsules and Powder for Oral suspension) orally or by intravenous infusion (Solution for Infusion), the route being dependent on the clinical state of the patient. On transferring from the intravenous to the oral route, or vice versa, there is no need to change the daily dose. The capsules should be swallowed whole and independent of food intake</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 Hypersensitivity to the active substance, to related azole 
substances, or to any of the excipients listed in section 6.1. 
❑ Coadministration of terfenadine is contraindicated in patients 
receiving FUNZOL at multiple doses of 400 mg per day or higher 
based upon results of a multiple dose interaction study. 
❑ Coadministration of other medicinal products known to prolong the 
QT interval and which are metabolised via the cytochrome P450 
(CYP) 3A4 such as cisapride, astemizole, pimozide, quinidine and 
erythromycin are contraindicated in patients receiving fluconazole 
(see sections 4.4 and 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tinea capitis Fluconazole has been studied for treatment of tinea capitis in children. It was shown not to be superior to griseofulvin and the overall success rate was less than 20%. Therefore, Fluconazole should not be used for tinea capitis. SPC FUNZOL 150 mg CAPSULES ❑ Cryptococcosis The evidence for efficacy of fluconazole in the treatment of cryptococcosis of other sites (e.g., pulmonary and cutaneous cryptococcosis) is limited, which prevents dosing recommendations. ❑ Deep endemic mycoses The evidence for efficacy of fluconazole in the treatment of other forms of endemic mycoses such as paracoccidioidomycosis, lymphocutaneous sporotrichosis and histoplasmosis is limited, which prevents specific dosing recommendations. ❑ Renal system FUNZOL should be administered with caution to patients with renal dysfunction (see section 4.2). ❑ Adrenal insufficiency Ketoconazole is known to cause adrenal insufficiency, and this could also although rarely seen be applicable to fluconazole. Adrenal insufficiency relating to concomitant treatment with prednisone is described in section 4.5 &ldquo;the effect of fluconazole on other medicinal products&rdquo; ❑ Hepatobiliary system FUNZOL should be administered with caution to patients with liver dysfunction. Fluconazole has been associated with rare cases of serious hepatic toxicity including fatalities, primarily in patients with serious underlying medical conditions. In cases of fluconazole associated hepatotoxicity, no obvious relationship to total daily dose, duration of therapy, sex or age of patient has been observed. Fluconazole hepatotoxicity has usually been reversible on discontinuation of therapy. Patients who develop abnormal liver function tests during fluconazole therapy must be monitored closely for the development of more serious hepatic injury. The patient should be informed of suggestive symptoms of serious hepatic effect (important asthenia, anorexia, persistent nausea, vomiting and jaundice). Treatment of fluconazole should be SPC FUNZOL 150 mg CAPSULES immediately discontinued and the patient should consult a physician. ❑ Cardiovascular system Some azoles, including fluconazole, have been associated with prolongation of the QT interval on the electrocardiogram. Fluconazole causes QT prolongation via the inhibition of Rectifier Potassium Channel current (Ikr). The QT prolongation caused by other medicinal products (such as amiodarone) may be amplified via the inhibition of cytochrome P450 (CYP) 3A4. During postmarketing surveillance, there have been very rare cases of QT prolongation and torsades de pointes in patients taking FUNZOL. These reports included seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities and concomitant treatment that may have been contributory. Patients with hypokalemia and advanced cardiac failure are at an increased risk for the occurrence of life-threatening ventricular arrhythmias and torsades de pointes. Fluconazole should be administered with caution to patients with these potentially proarrhythmic conditions. Coadministration of other medicinal products known to prolong the QT interval and which are metabolised via the cytochrome P450 (CYP) 3A4 is contraindicated (see sections 4.3 and 4.5). ❑ Halofantrine Halofantrine has been shown to prolong QTc interval at the recommended therapeutic dose and is a substrate of CYP3A4. The concomitant use of fluconazole and halofantrine is therefore not recommended (see section 4.5). ❑ Dermatological reactions Patients have rarely developed exfoliative cutaneous reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, during treatment with fluconazole. AIDS patients are more prone to the development of severe cutaneous reactions to many medicinal products. If a rash, which is considered attributable to fluconazole, develops in a patient treated for a superficial fungal infection, further therapy with this medicinal product should be discontinued. If patients with invasive/systemic fungal infections develop rashes, they should be monitored closely and fluconazole discontinued if bullous lesions or erythema multiforme develop. SPC FUNZOL 150 mg CAPSULES ❑ Hypersensitivity In rare cases anaphylaxis has been reported (see section 4.3). ❑ Cytochrome P450 Fluconazole is a moderate CYP2C9 and CYP3A4 inhibitor. Fluconazole is also a strong inhibitor of CYP2C19. Fluconazole treated patients who are concomitantly treated with medicinal products with a narrow therapeutic window metabolised through CYP2C9, CYP2C19 and CYP3A4, should be monitored (see section 4.5). ❑ Terfenadine The coadministration of fluconazole at doses lower than 400 mg per day with terfenadine should be carefully monitored (see sections 4.3 and 4.5). ❑ Candidiasis Studies have shown an increasing prevalence of infections with Candida species other than C. albicans. These are often inherently resistant (e.g. C. krusei and C. auris) or show reduced susceptibility to fluconazole (C. glabrata). Such infections may require alternative antifungal therapy secondary to treatment failure. Therefore, prescribers are advised to take into account the prevalence of resistance in various Candida species to fluconazole. ❑ Excipients Capsules contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucosegalactose malabsorption should not take this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant use of the following other medicinal products is contraindicated: Cisapride: There have been reports of cardiac events including torsades de pointes in patients to whom fluconazole and cisapride were coadministered. A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval. Concomitant treatment with fluconazole and cisapride is contraindicated (see section 4.3). Terfenadine: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with terfenadine, interaction studies have been performed. One study at a 200 mg daily dose of fluconazole failed to demonstrate a prolongation in QTc interval. Another study at a 400 mg and 800 mg daily dose of fluconazole demonstrated that fluconazole taken in doses of 400 mg per day or greater significantly increases plasma SPC FUNZOL 150 mg CAPSULES levels of terfenadine when taken concomitantly. The combined use of fluconazole at doses of 400 mg or greater with terfenadine is contraindicated (see section 4.3). The coadministration of fluconazole at doses lower than 400 mg per day with terfenadine should be carefully monitored. Astemizole: Concomitant administration of fluconazole with astemizole may decrease the clearance of astemizole. Resulting increased plasma concentrations of astemizole can lead to QT prolongation and rare occurrences of torsades de pointes. Coadministration of fluconazole and astemizole is contraindicated (see section 4.3). Pimozide: Although not studied in vitro or in vivo, concomitant administration of fluconazole with pimozide may result in inhibition of pimozide metabolism. Increased pimozide plasma concentrations can lead to QT prolongation and rare occurrences of torsades de pointes. Coadministration of fluconazole and pimozide is contraindicated (see section 4.3). Quinidine: Although not studied in vitro or in vivo, concomitant administration of fluconazole with quinidine may result in inhibition of quinidine metabolism. Use of quinidine has been associated with QT prolongation and rare occurrences of torsades de pointes. Coadministration of fluconazole and quinidine is contraindicated (see section 4.3). Erythromycin: Concomitant use of fluconazole and erythromycin has the potential to increase the risk of cardiotoxicity (prolonged QT interval, torsades de pointes) and consequently sudden heart death. Coadministration of fluconazole and erythromycin is contraindicated (see section 4.3). Concomitant use of the following other medicinal products cannot be recommended: Halofantrine: Fluconazole can increase halofantrine plasma concentration due to an inhibitory effect on CYP3A4. Concomitant use of fluconazole and halofantrine has the potential to increase the risk of cardiotoxicity (prolonged QT interval, torsades de pointes) and consequently sudden heart death. This combination should be avoided (see section 4.4). Concomitant use that should be used with caution: Amiodarone: Concomitant administration of fluconazole with amiodarone may increase QT prolongation. Caution must be exercised if the concomitant use of fluconazole and amiodarone is necessary, notably with high dose fluconazole (800 mg). Concomitant use of the following other medicinal products leads to precautions and dose adjustments: The effect of other medicinal products on fluconazole Rifampicin: Concomitant administration of fluconazole and rifampicin resulted in a 25% decrease in the AUC and a 20% shorter half-life of fluconazole. In patients receiving concomitant rifampicin, an increase of the fluconazole dose should be considered. Interaction studies have shown that when oral fluconazole is coadministered with food, cimetidine, antacids or following total body irradiation for bone marrow transplantation, no clinically significant impairment of fluconazole absorption occurs. SPC FUNZOL 150 mg CAPSULES Hydrochlorothiazide: In a pharmacokinetic interaction study, coadministration of multiple-dose hydrochlorothiazide to healthy volunteers receiving fluconazole increased plasma concentration of fluconazole by 40%. An effect of this magnitude should not necessitate a change in the fluconazole dose regimen in subjects receiving concomitant diuretics. The effect of fluconazole on other medicinal products Fluconazole is a moderate inhibitor of cytochrome P450 (CYP) isoenzymes 2C9 and 3A4. Fluconazole is also a strong inhibitor of the isozyme CYP2C19. In addition to the observed/documented interactions mentioned below, there is a risk of increased plasma concentration of other compounds metabolised by CYP2C9, CYP2C19 and CYP3A4 coadministered with fluconazole. Therefore, caution should be exercised when using these combinations and the patients should be carefully monitored. The enzyme inhibiting effect of fluconazole persists 4-5 days after discontinuation of fluconazole treatment due to the long half-life of fluconazole (see section 4.3). Abrocitinib: Fluconazole (inhibitor of CYP2C19, 2C9, 3A4) increased exposure of abrocitinib active moiety by 155%. If co-administered with fluconazole, adjust the dose of abrocitinib as instructed in the abrocitinib prescribing information. Alfentanil: During concomitant treatment with fluconazole (400 mg) and intravenous alfentanil (20 &mu;g/kg) in healthy volunteers the alfentanil AUC 10 increased 2-fold, probably through inhibition of CYP3A4.Dose adjustment of alfentanil may be necessary. Amitriptyline, nortriptyline: Fluconazole increases the effect of amitriptyline and nortriptyline. 5-nortriptyline and/or S-amitriptyline may be measured at initiation of the combination therapy and after one week. Dose of amitriptyline/nortriptyline should be adjusted, if necessary. Amphotericin B: Concurrent administration of fluconazole and amphotericin B in infected normal and immunosuppressed mice showed the following results: a small additive antifungal effect in systemic infection with C. albicans, no interaction in intracranial infection with Cryptococcus neoformans, and antagonism of the two medicinal products in systemic infection with Aspergillus fumigatus. The clinical significance of results obtained in these studies is unknown. Anticoagulants: In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, haematuria, and melena) have been reported, in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin. During concomitant treatment with fluconazole and warfarin the prothrombin time was prolonged up to 2- fold, probably due to an inhibition of the warfarin metabolism through CYP2C9. In patients receiving coumarin-type or indanedione anticoagulants concurrently with fluconazole the prothrombin time should be carefully monitored. Dose adjustment of the anticoagulant may be necessary. Benzodiazepines (short acting), i.e., midazolam, triazolam: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. Concomitant intake of fluconazole 200 mg and midazolam 7.5 mg orally increased the midazolam AUC and half-life 3.7-fold and 2.2-fold, respectively. Fluconazole 200 mg daily given SPC FUNZOL 150 mg CAPSULES concurrently with triazolam 0.25 mg orally increased the triazolam AUC and half-life 4.4-fold and 2.3-fold, respectively. Potentiated and prolonged effects of triazolam have been observed at concomitant treatment with fluconazole. If concomitant benzodiazepine therapy is necessary in patients being treated with fluconazole, consideration should be given to decreasing the benzodiazepine dose, and the patients should be appropriately monitored. Carbamazepine: Fluconazole inhibits the metabolism of carbamazepine and an increase in serum carbamazepine of 30% has been observed. There is a risk of developing carbamazepine toxicity. Dose adjustment of carbamazepine may be necessary depending on concentration measurements/effect. Calcium channel blockers: Certain calcium channel antagonists (nifedipine, isradipine, amlodipine, verapamil and felodipine) are metabolised by CYP3A4. Fluconazole has the potential to increase the systemic exposure of the calcium channel antagonists. Frequent monitoring for adverse events is recommended. Celecoxib: During concomitant treatment with fluconazole (200 mg daily) and celecoxib (200 mg) the celecoxib Cmax and AUC increased by 68% and 134%, respectively. Half of the celecoxib dose may be necessary when combined with fluconazole. Cyclophosphamide: Combination therapy with cyclophosphamide and fluconazole results in an increase in serum bilirubin and serum creatinine. The combination may be used while taking increased consideration to the risk of increased serum bilirubin and serum creatinine. Fentanyl: One fatal case of fentanyl intoxication due to possible fentanyl fluconazole interaction was reported. Furthermore, it was shown in healthy volunteers that fluconazole delayed the elimination of fentanyl significantly. Elevated fentanyl concentration may lead to respiratory depression. Patients should be monitored closely for the potential risk of respiratory depression. Dosage adjustment of fentanyl may be necessary. HMG CoA reductase inhibitors: The risk of myopathy and rhabdomyolysis increases when fluconazole is coadministered with HMG-CoA reductase inhibitors metabolised through CYP3A4, such as atorvastatin and simvastatin, or through CYP2C9, such as fluvastatin. If concomitant therapy is necessary, the patient should be observed for symptoms of myopathy and rhabdomyolysis and creatine kinase should be monitored. HMG-CoA reductase inhibitors should be discontinued if a marked increase in creatine kinase is observed or myopathy/rhabdomyolysis is diagnosed or suspected. Ibrutinib: Moderate inhibitors of CYP3A4 such as fluconazole increase plasma ibrutinib concentrations and may increase risk of toxicity. If the combination cannot be avoided, reduce the dose of ibrutinib to 280 mg once daily (two capsules) for the duration of the inhibitor use and provide close clinical monitoring. Ivacaftor (alone or combined with drugs in the same therapeutic class): Coadministration with ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, increased ivacaftor exposure by 3-fold and hydroxymethyl-ivacaftor (M1) exposure by 1.9-fold. A reduction of the ivacaftor (alone or combined) dose is necessary as instructed in the ivacaftor (alone or combined) prescribing information. SPC FUNZOL 150 mg CAPSULES Olaparib: Moderate inhibitors of CYP3A4 such as fluconazole increase olaparib plasma concentrations; concomitant use is not recommended. If the combination cannot be avoided, limit the dose of olaparib to 200 mg twice daily. Immunosuppressors (i.e., ciclosporin, everolimus, sirolimus and tacrolimus): Ciclosporin: Fluconazole significantly increases the concentration and AUC of ciclosporin. During concomitant treatment with fluconazole 200 mg daily and ciclosporin (2.7 mg/kg/day) there was a 1.8-fold increase in ciclosporin AUC. This combination may be used by reducing the dose of ciclosporin depending on ciclosporin concentration. Everolimus: Although not studied in vivo or in vitro, fluconazole may increase serum concentrations of everolimus through inhibition of CYP3A4. Sirolimus: Fluconazole increases plasma concentrations of sirolimus presumably by inhibiting the metabolism of sirolimus via CYP3A4 and P-glycoprotein. This combination may be used with a dose adjustment of sirolimus depending on the effect/concentration measurements. Tacrolimus: Fluconazole may increase the serum concentrations of orally administered tacrolimus up to 5 times due to inhibition of tacrolimus metabolism through CYP3A4 in the intestines. No significant pharmacokinetic changes have been observed when tacrolimus is given intravenously. Increased tacrolimus levels have been associated with nephrotoxicity. Dose of orally administered tacrolimus should be decreased depending on tacrolimus concentration. Lurasidone: Moderate inhibitors of CYP3A4 such as fluconazole may increase lurasidone plasma concentrations. If concomitant use cannot be avoided, reduce the dose of lurasidone as instructed in the lurasidone prescribing information. Losartan: Fluconazole inhibits the metabolism of losartan to its active metabolite (E31 74) which is responsible for most of the angiotensin II-receptor antagonism which occurs during treatment with losartan. Patients should have their blood pressure monitored continuously. Methadone: Fluconazole may enhance the serum concentration of methadone. Dose adjustment of methadone may be necessary. Non-steroidal anti-inflammatory drugs: The Cmax and AUC of flurbiprofen was increased by 23% and 81%, respectively, when coadministered with fluconazole compared to administration of flurbiprofen alone. Similarly, the Cmax and AUC of the pharmacologically active isomer [S-(+)-ibuprofen] was increased by 15% and 82%, respectively, when fluconazole was coadministered with racemic ibuprofen (400 mg) compared to administration of racemic ibuprofen alone. Although not specifically studied, fluconazole has the potential to increase the systemic exposure of other NSAIDs that are metabolised by CYP2C9 (e.g., naproxen, lornoxicam, meloxicam, diclofenac). Frequent monitoring for adverse events and toxicity related to NSAIDs is recommended. Adjustment of dose of NSAIDs may be needed. Phenytoin: Fluconazole inhibits the hepatic metabolism of phenytoin. Concomitant repeated administration of 200 mg fluconazole and 250 mg phenytoin intravenously, caused an increase of the phenytoin AUC24 by 75% and Cmin by 128%. With SPC FUNZOL 150 mg CAPSULES coadministration, serum phenytoin concentration levels should be monitored in order to avoid phenytoin toxicity. Prednisone: There was a case report that a liver-transplanted patient treated with prednisone developed acute adrenal cortex insufficiency when a three-month therapy with fluconazole was discontinued. The discontinuation of fluconazole presumably caused an enhanced CYP3A4 activity which led to increased metabolism of prednisone. Patients on long-term treatment with fluconazole and prednisone should be carefully monitored for adrenal cortex insufficiency when fluconazole is discontinued. Rifabutin: Fluconazole increases serum concentrations of rifabutin, leading to increase in the AUC of rifabutin up to 80%. There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered. In combination therapy, symptoms of rifabutin toxicity should be taken into consideration. Saquinavir: Fluconazole increases the AUC and Cmax of saquinavir with approximately 50% and 55% respectively, due to inhibition of saquinavir&#39;s hepatic metabolism by CYP3A4 and inhibition of P-glycoprotein. Interaction with saquinavir/ritonavir has not been studied and might be more marked. Dose adjustment of saquinavir may be necessary. Sulfonylureas: Fluconazole has been shown to prolong the serum half-life of concomitantly administered oral sulfonylureas (e.g., chlorpropamide, glibenclamide, glipizide, tolbutamide) in healthy volunteers. Frequent monitoring of blood glucose and appropriate reduction of sulfonylurea dose is recommended during coadministration. Theophylline: In a placebo-controlled interaction study, the administration of fluconazole 200 mg for 14 days resulted in an 18% decrease in the mean plasma clearance rate of theophylline. Patients who are receiving high dose theophylline or who are otherwise at increased risk for theophylline toxicity should be observed for signs of theophylline toxicity while receiving fluconazole. Therapy should be modified if signs of toxicity develop. Tofacitinib: Exposure of tofacitinib is increased when tofacitinib is co-administered with medications that result in both moderate inhibition of CYP3A4 and strong inhibition of CYP2C19 (e.g., fluconazole). Therefore, it is recommended to reduce tofacitinib dose to 5 mg once daily when it is combined with these drugs. Tolvaptan: Exposure to tolvaptan is significantly increased (200% in AUC; 80% in Cmax) when tolvaptan, a CYP3A4 substrate, is co-administered with fluconazole, a moderate CYP3A4 inhibitor, with risk of significant increase in adverse reactions particularly significant diuresis, dehydration and acute renal failure. In case of concomitant use, the tolvaptan dose should be reduced as instructed in the tolvaptan prescribing information and the patient should be frequently monitored for any adverse reactions associated with tolvaptan. Vinca alkaloids: Although not studied, fluconazole may increase the plasma levels of the vinca alkaloids (e.g., vincristine and vinblastine) and lead to neurotoxicity, which is possibly due to an inhibitory effect on CYP3A4. Vitamin A: Based on a case-report in one patient receiving combination therapy with all-trans-retinoid acid (an acid form of vitamin A) and fluconazole, CNS related undesirable effects have developed in the form of pseudotumour cerebri, which SPC FUNZOL 150 mg CAPSULES disappeared after discontinuation of fluconazole treatment. This combination may be used but the incidence of CNS related undesirable effects should be borne in mind. Voriconazole: (CYP2C9, CYP2C19 and CYP3A4 inhibitor): Coadministration of oral voriconazole (400 mg Q12h for 1 day, then 200 mg Q12h for 2.5 days) and oral fluconazole (400 mg on day 1, then 200 mg Q24h for 4 days) to 8 healthy male subjects resulted in an increase in Cmax and AUC of voriconazole by an average of 57% (90% CI: 20%, 107%) and 79% (90% CI: 40%, 128%), respectively. The reduced dose and/or frequency of voriconazole and fluconazole that would eliminate this effect have not been established. Monitoring for voriconazole associated adverse events is recommended if voriconazole is used sequentially after fluconazole. Zidovudine: Fluconazole increases Cmax and AUC of zidovudine by 84% and 74%, respectively, due to an approx. 45% decrease in oral zidovudine clearance. The halflife of zidovudine was likewise prolonged by approximately 128% following combination therapy with fluconazole. Patients receiving this combination should be monitored for the development of zidovudine-related adverse reactions. Dose reduction of zidovudine may be considered. Azithromycin: An open-label, randomized, three-way crossover study in 18 healthy subjects assessed the effect of a single 1200 mg oral dose of azithromycin on the pharmacokinetics of a single 800 mg oral dose of fluconazole as well as the effects of fluconazole on the pharmacokinetics of azithromycin. There was no significant pharmacokinetic interaction between fluconazole and azithromycin. Oral contraceptives: Two pharmacokinetic studies with a combined oral contraceptive have been performed using multiple doses of fluconazole. There were no relevant effects on hormone level in the 50 mg fluconazole study, while at 200 mg daily, the AUCs of ethinyl estradiol and levonorgestrel were increased 40% and 24%, respectively. Thus, multiple dose use of fluconazole at these doses is unlikely to have an effect on the efficacy of the combined oral contraceptive</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy An observational study has suggested an increased risk of spontaneous abortion in women treated with fluconazole during the first trimester. Data from several thousand pregnant women treated with a cumulative dose of &le; 150 mg of fluconazole, administered in the first trimester, show no increase in the overall risk of malformations in the foetus. In one large observational cohort study, first trimester exposure to oral fluconazole was associated with a small increased risk of musculoskeletal malformations, corresponding to approximately 1 additional case per 1000 women treated with cumulative doses &le; 450 mg compared with women treated with topical azoles and to approximately 4 additional cases per 1000 women treated with cumulative doses over 450 mg. The adjusted relative risk was 1.29 (95% CI 1.05 to 1.58) for 150 mg oral fluconazole and 1.98 (95% CI 1.23 to 3.17) for doses over 450 mg fluconazole. There have been reports of multiple congenital abnormalities (including brachycephalia, ears dysplasia, giant anterior fontanelle, femoral bowing and radiohumeral synostosis) in infants whose mothers were treated for at least three or more SPC FUNZOL 150 mg CAPSULES months with high doses (400 - 800 mg daily) of fluconazole for coccidioidomycosis. The relationship between fluconazole uses and these events is unclear. Studies in animals have shown reproductive toxicity (see section 5.3). Before becoming pregnant a washout period of approximately 1 week (corresponding to 5-6 half-lives) is recommended after a single-dose or discontinuation of a course of treatment (see section 5.2). Fluconazole in standard doses and short-term treatments should not be used in pregnancy unless clearly necessary. Fluconazole in high dose and/or in prolonged regimens should not be used during pregnancy except for potentially life-threatening infections. Breast-feeding Fluconazole passes into breast milk to reach concentrations similar to those in plasma (see section 5.2). Breast-feeding may be maintained after a single dose of 150 mg fluconazole. Breast-feeding is not recommended after repeated use or after high dose fluconazole. The developmental and health benefits of breast-feeding should be considered along with the mother&#39;s clinical need for Funzol and any potential adverse effects on the breast-fed child from Funzol or from the underlying maternal condition. Fertility Fluconazole did not affect the fertility of male or female rats (see section 5.3)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies have been performed on the effects of Funzol on the ability to drive or use machines. Patients should be warned about the potential for dizziness or seizures (see section 4.8) while taking Funzol and should be advised not to drive or operate machines if any of these symptoms occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of safety profile Drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported in association with fluconazole treatment (see section 4.4). The most frequently (&ge;1/100 to &lt;1/10) reported adverse reactions are headache, abdominal pain, diarrhoea, nausea, vomiting, alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased and rash. The following adverse reactions have been observed and reported during treatment with Funzol with the following frequencies: Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data). SPC FUNZOL 150 mg CAPSULES System Organ Class Common Uncommon Rare Not Known Blood and the lymphatic system disorders Anaemia Agranulocytosis, leukopenia, thrombocytopenia, neutropenia Immune system disorders Anaphylaxis Metabolism and nutrition disorders Decreased appetite Hypercholesterolaemia, hypertriglyceridaemia, hypokalaemia Psychiatric disorders Somnolence, insomnia Nervous system disorders Headache Seizures, paraesthesia, dizziness, taste perversion Tremor Ear and labyrinth disorders Vertigo Cardiac disorders Torsade de pointes (see section 4.4), QT prolongation (see section 4.4) Gastrointestinal disorders Abdominal pain, vomiting, diarrhoea, nausea Constipation dyspepsia, flatulence, dry mouth Hepatobiliary disorders Alanine aminotransferase increased (see section 4.4), aspartate aminotransferase increased (see section 4.4), blood alkaline phosphatase increased (see section 4.4) Cholestasis (see section 4.4), jaundice (see section 4.4), bilirubin increased (see section 4.4) Hepatic failure (see section 4.4), hepatocellular necrosis (see section 4.4), hepatitis (see section 4.4), hepatocellular damage (see section 4.4) Skin and subcutaneous tissue disorders Rash (see section 4.4) Drug eruption* (see section 4.4), urticaria (see section 4.4), pruritus, increased sweating Toxic epidermal necrolysis, (see section 4.4), Stevens-Johnson syndrome (see section 4.4), acute generalised exanthematouspustulosis (see section 4.4), dermatitis Drug reaction with eosinophilia and systemic symptoms (DRESS) SPC FUNZOL 150 mg CAPSULES System Organ Class Common Uncommon Rare Not Known exfoliative, angioedema, face oedema, alopecia Musculoskeletal and connective tissue disorders Myalgia General disorders and administration site conditions Fatigue, malaise, asthenia, fever * Including Fixed Drug Eruption Paediatric population The pattern and incidence of adverse reactions and laboratory abnormalities recorded during paediatric clinical trials, excluding the genital candidiasis indication, are comparable to those seen in adults. To report any side effect (s): Saudi Arabia: National Pharmacovigilance &amp; Drug Safety Centre (NPC) To report any side effect(s): The National Pharmacovigilance Center (NPC): Fax: +966-11-205-7662, SFDA Call Center: 19999, E-mail: npc.drug@sfda.gov.sa, Website: http://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There have been reports of overdose with Funzol. Hallucination and paranoid behaviour have been concomitantly reported. In the event of overdose, symptomatic treatment (with supportive measures and gastric lavage if necessary) may be adequate. Fluconazole is largely excreted in the urine; forced volume diuresis would probably increase the elimination rate. A three-hour haemodialysis session decreases plasma levels by approximately 50%</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antimycotics for systemic use, triazole derivatives, ATC code: J02AC01. Mechanism of action Fluconazole is a triazole antifungal agent. Its primary mode of action is the inhibition of fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylation, an essential step in fungal ergosterol biosynthesis. The accumulation of 14 alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell membrane and may be responsible for the antifungal activity of fluconazole. Fluconazole has been shown to be more selective for fungal cytochrome P-450 enzymes than for various mammalian cytochrome P-450 enzyme systems. Fluconazole 50 mg daily given up to 28 days has been shown not to effect testosterone plasma concentrations in males or steroid concentration in females of child-bearing age. Fluconazole 200 mg to 400 mg daily has no clinically significant effect on endogenous steroid levels or on ACTH stimulated response in healthy male volunteers. Interaction studies with antipyrine indicate that single or multiple doses of fluconazole 50 mg do not affect its metabolism. Susceptibility in vitro In vitro, fluconazole displays antifungal activity against clinically common Candida species (including C. albicans, C. parapsilosis, C. tropicalis). C. glabrata shows reduced susceptibility to fluconazole while C. krusei and C. auris are resistant to fluconazole. The MICs and epidemiological cut-off value (ECOFF) of fluconazole for C. guilliermondii are higher than for C. albicans. Fluconazole also exhibits activity in vitro against Cryptococcus neoformans and Cryptococcus. gattii as well as the endemic moulds Blastomyces dermatiditis, Coccidioides immitis, Histoplasma capsulatum and Paracoccidioides brasiliensis. Pharmacokinetic/pharmacodynamic relationship In animal studies, there is a correlation between MIC values and efficacy against experimental mycoses due to Candida spp. In clinical studies, there is an almost 1:1 linear relationship between the AUC and the dose of fluconazole. There is also a direct though imperfect relationship between the AUC or dose and a successful clinical response of oral candidosis and to a lesser extent candidaemia to treatment. Similarly, cure is less likely for infections caused by strains with a higher fluconazole MIC. Mechanisms of resistance Candida spp have developed a number of resistance mechanisms to azole antifungal agents. Fungal strains which have developed one or more of these resistance mechanisms are known to exhibit high minimum inhibitory concentrations (MICs) to fluconazole which impacts adversely efficacy in vivo and clinically. In usually susceptible species of Candida, the most commonly encountered mechanism of resistance development involves the target enzymes of the azoles, which are responsible for the biosynthesis of ergosterol. Resistance may be caused by SPC FUNZOL 150 mg CAPSULES mutation, increased production of an enzyme, drug efflux mechanisms, or the development of compensatory pathways. There have been reports of superinfection with Candida species other than C. albicans, which often have inherently reduced susceptibility (C. glabrata) or resistance to fluconazole (e.g., C. krusei, C. auris). Such infections may require alternative antifungal therapy. The resistance mechanisms have not been completely elucidated in some intrinsically resistant (C. krusei) or emerging (C. auris) species of Candida. EUCAST Breakpoints Based on analyses of pharmacokinetic/pharmacodynamic (PK/PD) data, susceptibility in vitro and clinical response EUCAST-AFST (European Committee on Antimicrobial Susceptibility Testing-Subcommitte on Antifungal Susceptibility Testing) has determined breakpoints for fluconazole for Candida species (EUCAST Fluconazole rationale document (2020)-version 3; European Committee on Antimicrobial Susceptibility Testing, Antifungal Agents, Breakpoint tables for interpretation of MICs, Version 10.0, valid from 2020-02-04). These have been divided into non-species related breakpoints; which have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species, and species related breakpoints for those species most frequently associated with human infection. These breakpoints are given in the table below: Antifungal Species-related breakpoints (S&le;/R&gt;) in mg/L Non-species related breakpointsA S in mg/L Candida albicans Candida dubliniensis Candida glabrata Candida krusei Candida parapsilosis Candida tropicalis Fluconazole 2/4 2/4 0.001*/16 -- 2/4 2/4 2/4 S = Susceptible, R = Resistant A = non-species related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species. They are for use only for organisms that do not have specific breakpoints. -- = Susceptibility testing not recommended as the species is a poor target for therapy with the medicinal product. * = The entire C. glabrata is in the I category. MICs against C. glabrata should be interpreted as resistant when above 16 mg/L. Susceptible category (&le;0.001 mg/L) is simply to avoid misclassification of &quot;I&quot; strains as &quot;S&quot; strains. I - Susceptible, increased exposure: A microorganism is categorised as Susceptible, increased exposure when there is a high likelihood of therapeutic success because exposure to the agent is increased by adjusting the dosing regimen or by its concentration at the site of infection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetic properties of fluconazole are similar following administration by the intravenous or oral route. Absorption After oral administration fluconazole is well absorbed, and plasma levels (and systemic bioavailability) are over 90% of the levels achieved after intravenous administration. Oral absorption is not affected by concomitant food intake. Peak plasma concentrations in the fasting state occur between 0.5 and 1.5 hours post-dose. Plasma concentrations are proportional to dose. Ninety percent steady state levels are reached by day 4-5 with multiple once daily dosing. Administration of a loading dose (on day 1) of twice the usual daily dose enables plasma levels to approximate to 90% steady-state levels by day 2. Distribution The apparent volume of distribution approximates to total body water. Plasma protein binding is low (11-12%). Fluconazole achieves good penetration in all body fluids studied. The levels of fluconazole in saliva and sputum are similar to plasma levels. In patients with fungal meningitis, fluconazole levels in the CSF are approximately 80% the corresponding plasma levels. High skin concentration of fluconazole, above serum concentrations, are achieved in the stratum corneum, epidermis-dermis and eccrine sweat. Fluconazole accumulates in the stratum corneum. At a dose of 50 mg once daily, the concentration of fluconazole after 12 days was 73 &micro;g/g and 7 days after cessation of treatment the concentration was still 5.8 &micro;g/g. At the 150 mg once-a-week dose, the concentration of fluconazole in stratum corneum on day 7 was 23.4 &micro;g/g and 7 days after the second dose was still 7.1 &micro;g/g. Concentration of fluconazole in nails after 4 months of 150 mg once-a-week dosing was 4.05 &micro;g/g in healthy and 1.8 &micro;g/g in diseased nails; and, fluconazole was still measurable in nail samples 6 months after the end of therapy. Biotransformation Fluconazole is metabolised only to a minor extent. Of a radioactive dose, only 11% is excreted in a changed form in the urine. Fluconazole is a moderate inhibitor of the isozymes CYP2C9 and CYP3A4 (see section 4.5). Fluconazole is also a strong inhibitor of the isozyme CYP2C19. Elimination Plasma elimination half-life for fluconazole is approximately 30 hours. The major route of excretion is renal, with approximately 80% of the administered dose appearing in the urine as unchanged medicinal product. Fluconazole clearance is proportional to creatinine clearance. There is no evidence of circulating metabolites. The long plasma elimination half-life provides the basis for single dose therapy for vaginal candidiasis, once daily and once weekly dosing for other indications. SPC FUNZOL 150 mg CAPSULES Pharmacokinetics in renal impairment In patients with severe renal insufficiency, (GFR&lt; 20 ml/min) half life increased from 30 to 98 hours. Consequently, reduction of the dose is needed. Fluconazole is removed by haemodialysis and to a lesser extent by peritoneal dialysis. After three hours of haemodialysis session, around 50% of fluconazole is eliminated from blood. Pharmacokinetics during lactation A pharmacokinetic study in ten lactating women, who had temporarily or permanently stopped breast-feeding their infants, evaluated fluconazole concentrations in plasma and breast milk for 48 hours following a single 150 mg dose of Funzol. Fluconazole was detected in breast milk at an average concentration of approximately 98% of those in maternal plasma. The mean peak breast milk concentration was 2.61 mg/L at 5.2 hours post-dose. The estimated daily infant dose of fluconazole from breast milk (assuming mean milk consumption of 150 ml/kg/day) based on the mean peak milk concentration is 0.39 mg/kg/day, which is approximately 40% of the recommended neonatal dose (&lt;2 weeks of age) or 13% of the recommended infant dose for mucosal candidiasis. Pharmacokinetics in children Pharmacokinetic data were assessed for 113 paediatric patients from 5 studies; 2 single-dose studies, 2 multiple-dose studies, and a study in premature neonates. Data from one study were not interpretable due to changes in formulation pathway through the study. Additional data were available from a compassionate use study. After administration of 2-8 mg/kg fluconazole to children between the ages of 9 months to 15 years, an AUC of about 38 &micro;g&middot;h/ml was found per 1 mg/kg dose units. The average fluconazole plasma elimination half-life varied between 15 and 18 hours and the distribution volume were approximately 880 ml/kg after multiple doses. A higher fluconazole plasma elimination half-life of approximately 24 hours was found after a single dose. This is comparable with the fluconazole plasma elimination halflife after a single administration of 3 mg/kg i.v. to children of 11 days-11 months old. The distribution volume in this age group was about 950 ml/kg. Experience with fluconazole in neonates is limited to pharmacokinetic studies in premature newborns. The mean age at first dose was 24 hours (range 9-36 hours) and mean birth weight was 0.9 kg (range 0.75-1.10 kg) for 12 pre-term neonates of average gestation around 28 weeks. Seven patients completed the protocol; a maximum of five 6 mg/kg intravenous infusions of fluconazole were administered every 72 hours. The mean half-life (hours) was 74 (range 44-185) on day 1 which decreased, with time to a mean of 53 (range 30-131) on day 7 and 47 (range 27-68) on day 13. The area under the curve (microgram.h/ml) was 271 (range 173-385) on day 1 and increased with a mean of 490 (range 292-734) on day 7 and decreased with a mean of 360 (range 167-566) on day 13. The volume of distribution (ml/kg) was 1183 (range 1070-1470) on day 1 and increased, with time, to a mean of 1184 (range 510- 2130) on day 7 and 1328 (range 1040-1680) on day 13. Pharmacokinetics in elderly A pharmacokinetic study was conducted in 22 subjects, 65 years of age or older receiving a single 50 mg oral dose of fluconazole. Ten of these patients were concomitantly receiving diuretics. The Cmax was 1.54 &micro;g/ml and occurred at 1.3 hours SPC FUNZOL 150 mg CAPSULES post-dose. The mean AUC was 76.4 &plusmn; 20.3 &micro;g&middot;h/ml, and the mean terminal half-life was 46.2 hours. These pharmacokinetic parameter values are higher than analogous values reported for normal young male volunteers. Coadministration of diuretics did not significantly alter AUC or Cmax. In addition, creatinine clearance (74 ml/min), the percent of medicinal product recovered unchanged in urine (0-24 h, 22%) and the fluconazole renal clearance estimates (0.124 ml/min/kg) for the elderly were generally lower than those of younger volunteers. Thus, the alteration of fluconazole disposition in the elderly appears to be related to reduced renal function characteristics of this group</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects in non-clinical studies were observed only at exposures considered sufficiently in excess of the human exposure indicating little relevance to clinical use. Carcinogenesis Fluconazole showed no evidence of carcinogenic potential in mice and rats treated orally for 24 months at doses of 2.5, 5, or 10 mg/kg/day (approximately 2-7 times the recommended human dose). Male rats treated with 5 and 10 mg/kg/day had an increased incidence of hepatocellular adenomas. Mutagenesis Fluconazole, with or without metabolic activation, was negative in tests for mutagenicity in 4 strains of Salmonella typhimurium, and in the mouse lymphoma L5178Y system. Cytogenetic studies in vivo (murine bone marrow cells, following oral administration of fluconazole) and in vitro (human lymphocytes exposed to fluconazole at 1000 &mu;g/ml) showed no evidence of chromosomal mutations. Reproductive toxicity Fluconazole did not affect the fertility of male or female rats treated orally with daily doses of 5, 10, or 20 mg/kg or with parenteral doses of 5, 25, or 75 mg/kg. There were no foetal effects at 5 or 10 mg/kg; increases in foetal anatomical variants (supernumerary ribs, renal pelvis dilation) and delays in ossification were observed at 25 and 50 mg/kg and higher doses. At doses ranging from 80 mg/kg to 320 mg/kg embryolethality in rats was increased and foetal abnormalities included wavy ribs, cleft palate, and abnormal cranio-facial ossification. The onset of parturition was slightly delayed at 20 mg/kg orally and dystocia and prolongation of parturition were observed in a few dams at 20 mg/kg and 40 mg/kg intravenously. The disturbances in parturition were reflected by a slight increase in the number of still-born pups and decrease of neonatal survival at these dose levels. These effects on parturition are consistent with the species-specific oestrogen-lowering property produced by high doses of fluconazole. Such a hormone change has not been observed in women treated with fluconazole (see section 5.1). SPC FUNZOL 150 mg CAPSULES</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>❑ Lactose D.C. ❑ Sodium Starch Glycollate ❑ Sodium Lauryl Sulphate ❑ Colloidal Anhydrous Silica ❑ Magnesium Stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg; C, protected from humidity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>FUNZOL 150 Capsules are cylindrical hard gelatin capsule of size 1 composed of blue clear body printed with Funzol and blue clear cap printed with 150 mg filled with white powder. □ Boxes of one blistered capsule of FUNZOL 150. □ Boxes of 168 blistered capsule of FUNZOL 150.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements, any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Jordanian Pharmaceutical Manufacturing Co. Ltd.
PO Box 151
Um Al-Amad 16197
Jordan
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>